Arcutis' ZORYVE Cream Shows Promise in Infant Atopic Dermatitis Trial
Event summary
- Arcutis' ZORYVE cream 0.05% achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) for 58% of infant participants in the INTEGUMENT-INFANT Phase 2 trial.
- The trial involved 101 infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis over a four-week period.
- ZORYVE cream demonstrated a consistent safety profile with no new safety signals identified, and adverse events were mild to moderate in severity.
- Arcutis plans to submit a supplemental New Drug Application (sNDA) for ZORYVE cream 0.05% for this age group in Q2 2026.
The big picture
Arcutis' positive Phase 2 trial results for ZORYVE cream in infants represent a strategic move to address the substantial unmet need in pediatric dermatology. Atopic dermatitis affects millions of children, with a significant portion developing symptoms within their first year. The company's focus on non-steroidal treatments aligns with broader industry trends towards safer, more targeted therapies for young patients.
What we're watching
- Regulatory Approval
- Whether the sNDA submission in Q2 2026 will be approved, expanding ZORYVE's market reach to younger patients.
- Market Expansion
- How successful ZORYVE can be in capturing a larger share of the pediatric atopic dermatitis market.
- Competitive Dynamics
- The pace at which competitors develop similar non-steroidal treatments for infant atopic dermatitis.
Related topics